May 20 (Reuters) - Advisers to the U.S. Food and Drug
Administration will discuss whether to recommend COVID-19
vaccines for 2025-26 for targetting the LP.8.1 subvariant,
documents filed on Tuesday showed.
The panel of advisers will make recommendations on the
selection of the 2025-2026 formula for COVID-19 vaccines for use
in the United States on Thursday.
(Reporting by Puyaan Singh and Christy Santhosh in Bengaluru;
Editing by Anil D'Silva)